This webinar takes place on Thursday May 22nd between 16.00 and 16.30 CEST / 15.00-15.30 BST / 10.00-10.30 AM EDT / 7.00-7.30 AM PDT.

Follow the link to register for the webinar. Please note that the presentation will be given during the live event only and on demand viewing at a later date will not be possible. Contact us for any questions.

 

REGISTER FOR LIVE WEBINAR

 

THIS WEBINAR IS ARRANGED BY CELLECTRICON AB. FOR MORE INFORMATION ON THE HANDLING OF YOUR PERSONAL INFORMATION, SEE OUR PRIVACY POLICY.

Abstract:

Oligonucleotide-based drugs, such as antisense oligonucleotides (ASOs) and short interfering RNAs (siRNAs), have emerged as promising therapeutic solutions for incurable central nervous system (CNS) diseases. However, these can trigger unexpected acute and delayed onset CNS-related adverse events in vivo, that can appear within hours to several weeks after administration. For accelerating development of safe therapeutic oligonucleotide-based drugs, more predictive in vitro assays that can be used at an early stage will be required.

Cellectricon has developed a broad range of assays for assessing effects of numerous modalities on e.g. neuronal function, cellular phenotype, and immune response. In this work, Cellectricon set out to explore the utility of select assays for detection of acute and delayed onset toxic effects of oligonucleotide-based drugs.

In the webinar, we will provide an overview of the assays evaluated, and how these are able to detect both acute and delayed onset oligonucleotide-induced toxicity.

Presented by:

Johan Pihl, CSO

Johan joined Cellectricon in 2005 and has been in R&D as well as commercial positions at the company. He has been involved in the development of Cellectricon’s proprietary technology platforms and intellectual property. Prior to his role as Chief Scientific Officer at Cellectricon, he was developing and overseeing the discovery services as Chief Operating Officer. Johan has a PhD in Chemistry from Chalmers University of Technology, Gothenburg, Sweden, and is the author and co-author of numerous scientific publications and patents.